Beta Bionics (BBNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, at 2:00 PM Pacific Time, with virtual attendance available.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of two Class I directors, Sean D. Carney and Christy Jones, to serve until the 2029 Annual Meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxies may vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Board has nominated two individuals for election as Class I directors.
Directors will serve until 2029 or until earlier death, resignation, or removal.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Beta Bionics
- 2025 net sales rose 54% to $100.3M, with Q4 margin at 59% and robust pharmacy channel growth.BBNX
Q4 202511 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and review governance, compensation, and ESG.BBNX
Proxy filing10 Apr 2026 - iLet’s automation and Mint patch pump drive growth as pharmacy models reshape the market.BBNX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Q1 outperformed expectations, with raised guidance and strong pharmacy-driven growth.BBNX
Bank of America 2025 Healthcare Conference3 Feb 2026 - 2024 net sales rose 443% to $65.1M, with rapid user growth and expanded pharmacy access.BBNX
Q4 202417 Dec 2025 - Rapid adoption, pharmacy growth, and innovation set the stage for accelerated profitability.BBNX
Piper Sandler 37th Annual Healthcare Conference3 Dec 2025 - IPO targets $114M+ to fund diabetes device growth, pipeline, and U.S. market expansion.BBNX
Registration Filing29 Nov 2025 - IPO funds will drive expansion of a fully automated insulin delivery platform for diabetes.BBNX
Registration Filing29 Nov 2025 - IPO targets $163M to fund growth of an automated insulin delivery platform for diabetes.BBNX
Registration Filing29 Nov 2025